First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Leisha A. Emens(Johns Hopkins University), P. Schmid(Queen Mary University of London)
Cited by 453
Related Papers
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
|Cancer Immunology Research|2015|814